U.S. T-cell Therapy Market Size & Outlook, 2021-2028
U.S. t-cell therapy market, 2018-2028 (US$M)
Related Markets
U.S. t-cell therapy market highlights
- The U.S. t-cell therapy market generated a revenue of USD 2,513.3 million in 2021 and is expected to reach USD 8,380.2 million by 2028.
- The U.S. market is expected to grow at a CAGR of 18.8% from 2022 to 2028.
- In terms of segment, commercialized was the largest revenue generating modality type in 2021.
- Research is the most lucrative modality type segment registering the fastest growth during the forecast period.
T-cell therapy market data book summary
| Market revenue in 2021 | USD 2,513.3 million |
| Market revenue in 2028 | USD 8,380.2 million |
| Growth rate | 18.8% (CAGR from 2021 to 2028) |
| Largest segment | Commercialized |
| Fastest growing segment | Research |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Research, Commercialized |
| Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.4% of the global t-cell therapy market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. t-cell therapy market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 486.0 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
T-cell Therapy Market Scope
T-cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. t-cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 57.24% in 2021. Horizon Databook has segmented the U.S. t-cell therapy market based on research, commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
The FDA approval of YESCARTA—manufactured by Kite Pharma—and KYMRIAH—manufactured by Novartis Pharmaceuticals Corporation—has been one of the major factors propelling market growth in the U.S. The use of CAR T-cell therapies has been approved for the treatment of ALL, refractory non-Hodgkin lymphoma, and refractory or relapsed large B cell lymphomas.
According to American Cancer Society, in 2019, approximately 5,930 new cases of ALL are expected to be diagnosed and 1,500 deaths are expected to occur due to the disease. In addition, ALL is not a common cancer among Americans and accounts for less than half of 1% of all cancers in the country.
According to NCBI (2017), the incidence of ALL in the U.S. is estimated at 1.6 per 100,000 individuals. The launch of CAR T- cell therapies has thus benefitted several patients suffering from ALL, affecting market growth positively.
Reasons to subscribe to U.S. t-cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. t-cell therapy market databook
-
Our clientele includes a mix of t-cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. t-cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into U.S. t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. t cell therapy market size, by modality type, 2018-2028 (US$M)
U.S. T-cell Therapy Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
